Stockscreener 앱 받기
40.49
2.84%
1.12
시간 외 거래:
40.51
0.02
+0.05%
전일 마감가:
$39.37
열려 있는:
$39.23
하루 거래량:
1.32M
Relative Volume:
0.97
시가총액:
$3.90B
수익:
$225.27M
순이익/손실:
$-140.06M
주가수익비율:
-25.35
EPS:
-1.5974
순현금흐름:
$-87.93M
1주 성능:
+8.64%
1개월 성능:
+43.12%
6개월 성능:
+6.95%
1년 성능:
+91.35%
1일 변동 폭
$38.63
$40.58
1주일 범위
$35.78
$40.58
52주 변동 폭
$21.22
$40.58
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
40.49 | 3.79B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-09-04 | 개시 | Barclays | Overweight |
| 2025-09-04 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 개시 | TD Cowen | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-26 | 개시 | Wells Fargo | Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
IDYA Maintains Outperform Rating by RBC Capital -- Price Target Lowered to $48 - GuruFocus
Ideaya Biosciences stock hits 52-week high at $39.28 By Investing.com - Investing.com South Africa
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion - simplywall.st
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBITDA forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to sales forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to earnings forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
IDEAYA Biosciences, Inc. Actuals & Estimates (SWB:30J) - TradingView
30J Forecast — Price Target — Prediction for 2027 - TradingView
(IDYA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
IDEAYA Biosciences, Inc. Actuals & Estimates (DUS:30J) - TradingView
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
IDEAYA Biosciences, Inc. Actuals & Estimates (NASDAQ:IDYA) - TradingView
IDEAYA lures 4 new hires with 98,000 stock options - Stock Titan
IDYA Forecast — Price Target — Prediction for 2027 - TradingView
IDEAYA Biosciences Shareholders Back Leadership, Governance Changes - TipRanks
Shareholders back IDEAYA (NASDAQ: IDYA) proposals as board names new chair - Stock Titan
IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Director at IDEAYA Biosciences (IDYA) receives 20,000-share stock option grant - Stock Titan
IDEAYA Biosciences (IDYA) director receives stock options on 20,000 shares - Stock Titan
IDEAYA (IDYA) director receives grant of 20,000 stock options - Stock Titan
IDEAYA (IDYA) director Terry Rosen receives 20,000 stock options at $30.57 - Stock Titan
IDEAYA (IDYA) director Scott Morrison receives grant of 20,000 stock options - Stock Titan
IDEAYA Biosciences (IDYA) director awarded stock options on 20,000 shares - Stock Titan
IDEAYA Biosciences Inc (IDYA) Institutional Confidence - TradingKey
IDEAYA Biosciences Inc (IDYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IDEAYA Biosciences Inc (IDYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IDEAYA Biosciences Inc (IDYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IDEAYA Biosciences elects Yujiro S. Hata board chairman - grafa.com
IDEAYA Biosciences, Inc. Announces Yujiro S. Hata Elected as Chairman of Board of Directors - marketscreener.com
IDEAYA Biosciences Elects CEO Yujiro Hata as Chairman - marketscreener.com
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors - Barchart.com
IDEAYA Biosciences Inc (IDYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
IDEAYA Biosciences (IDYA) Surges 4.31%: Breaking Through Resistance Levels?Earnings Beat Stocks - newsline.com
Responsive Playbooks and the IDYA Inflection - Stock Traders Daily
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class M - GuruFocus
Ideaya Biosciences stock rises on phase 1/2 cancer trial start By Investing.com - Investing.com South Africa
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
2.48%
자본화:
|
볼륨(24시간):